NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization850.78 mln
Float126 mln
Earnings Date07/30/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
0.74
Highly suspicious
1-Year Forecast
5.25
Attractive
Relative Strength
23
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-40.51
Deeply negative
Business Description
Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drug candidates work in complementary ways ? one reduces harmful viral proteins in the body, while the other helps the immune system recognize and fight the infection. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in developing its products.
